内皮素受体拮抗剂用于肺动脉高压的治疗进展

Progress of endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

肺动脉高压(PAH)是一类以肺血管阻力进行性升高为主要特征的心肺血管疾病,最终可导致右心衰竭甚至死亡。早期发现PAH患者中内皮素明显高于正常,可引起肺血管的持续收缩及重构。内皮素受体拮抗剂可阻断该通路进而起到降低肺高压的作用。但目前国内临床上对于该类药物了解甚少。本文参考国内外文献对内皮素受体拮抗剂在PAH中的作用机制及临床应用作简要综述,旨在指导临床用药,使更多患者获益。

PPulmonary arterial hypertension（PAH） is a pulmonary vascular disease by stepping up pulmonary vascular resistance and finally leads to right heart failure. Earlier studies showed that the endothelin-1 levels of pulmonary vascular in PAH patient is significantly higher than normal, which can cause sustained contraction and restructure. Endothelin receptor antagonist can be used to treat PAH. This review summarizes the mechanism and clinical application of endothelin receptor antagonists on PAH therapy.